In a boost for Merck (MRK), the U.S. Supreme Court tossed a lower-court ruling that had revived more than 500 lawsuits accusing the drug maker of failing to properly warn patients about thigh-bone fractures traced to its widely used Fosamax treatment for osteoporosis.

The justices want a federal appeals court to reconsider its 2018 ruling that allowed the lawsuits to proceed. Merck has argued that it tried to update warnings on the product labeling, but that the Food and Drug Administration rejected its efforts over disagreements with proposed wording about fracture risks. Last summer, the U.S. Solicitor General had urged the Supreme Court to review the case.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy